- Home
- NUVL vs ARW Comparison
NUVL vs ARW Comparison
Compare NUVL & ARW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- ARW
- Stock Information
- Founded
- NUVL 2017
- ARW 1935
- Country
- NUVL United States
- ARW United States
- Employees
- NUVL 200
- ARW N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- ARW Electronic Components
- Sector
- NUVL Health Care
- ARW Technology
- Exchange
- NUVL Nasdaq
- ARW Nasdaq
- Market Cap
- NUVL 6.0B
- ARW 6.7B
- IPO Year
- NUVL 2021
- ARW N/A
- Fundamental
- Price
- NUVL $83.09
- ARW $120.14
- Analyst Decision
- NUVL Strong Buy
- ARW Hold
- Analyst Count
- NUVL 9
- ARW 4
- Target Price
- NUVL $118.89
- ARW $115.75
- AVG Volume (30 Days)
- NUVL 396.7K
- ARW 514.3K
- Earning Date
- NUVL 11-11-2025
- ARW 10-30-2025
- Dividend Yield
- NUVL N/A
- ARW N/A
- EPS Growth
- NUVL N/A
- ARW N/A
- EPS
- NUVL N/A
- ARW 8.85
- Revenue
- NUVL N/A
- ARW $28,500,160,000.00
- Revenue This Year
- NUVL N/A
- ARW $10.00
- Revenue Next Year
- NUVL N/A
- ARW $5.98
- P/E Ratio
- NUVL N/A
- ARW $13.52
- Revenue Growth
- NUVL N/A
- ARW N/A
- 52 Week Low
- NUVL $55.54
- ARW $86.50
- 52 Week High
- NUVL $106.32
- ARW $137.80
- Technical
- Relative Strength Index (RSI)
- NUVL 56.32
- ARW 42.08
- Support Level
- NUVL $81.02
- ARW $118.25
- Resistance Level
- NUVL $86.34
- ARW $124.40
- Average True Range (ATR)
- NUVL 3.63
- ARW 2.49
- MACD
- NUVL 0.28
- ARW -0.00
- Stochastic Oscillator
- NUVL 66.33
- ARW 25.14
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About ARW Arrow Electronics Inc.
Arrow Electronics Inc. is a provider of products, services, and solutions to industrial and commercial users of electronic components and enterprise computing solutions. It has one of the world's broadest portfolios of product offerings available from electronic components and enterprise computing solutions suppliers, coupled with a range of services, solutions, and software, the company helps industrial and commercial customers introduce products, reduce their time to market, and enhance their overall competitiveness. The company has two business segments, the components business and the enterprise computing solutions.